501. Monoamine oxidase inhibition by phenelzine and brofaromine in healthy volunteers
- Author
-
Lucie Firkusny, P. R. Bieck, Hartmut Wollmann, Christina Schick, K. H. Antonin, Rainer Schulz, Michael H. Schwenk, and Erik Nilsson
- Subjects
Adult ,Male ,medicine.medical_specialty ,Monoamine Oxidase Inhibitors ,Monoamine oxidase ,Biological Availability ,Tyramine ,Blood Pressure ,Pharmacology ,Methoxyhydroxyphenylglycol ,Excretion ,chemistry.chemical_compound ,Vanilmandelic Acid ,Pharmacokinetics ,Phenelzine ,Piperidines ,Oral administration ,Heart Rate ,Internal medicine ,Brofaromine ,Blood plasma ,medicine ,Humans ,Pharmacology (medical) ,Chemistry ,Tryptamines ,Endocrinology ,medicine.drug - Abstract
The two monoamine oxidase (MAO) inhibitors phenelzine and brofaromine given for 2 to 3 weeks were compared in six volunteers. Blood pressure sensitivity to intravenous tyramine increased 2.6-fold during phenelzine (60 mg/day) and 4.8-fold during brofaromine, whereas sensitivity to oral tyramine increased more during phenelzine (15.7-fold vs 8.5-fold). After withdrawal of phenelzine, pressor sensitivity to oral tyramine returned to control values within 2 and for more than 8 weeks. Relative bioavailability of conjugated tyramine was elevated sixfold by brofaromine and 11.6-fold by phenelzine. Urinary elimination of tryptamine increased during phenelzine and brofaromine to 12.7-fold and threefold, respectively. 3-Methoxy-4-hydroxyphenylglycol (MHPG) and 3-methoxy-4-hydroxymandelic acid (VMA) excretion decreased during brofaromine significantly by 72% and 49%, respectively. The nonsignificant decrease of MHPG excretion and the increase of intravenous tyramine pressor sensitivity caused by phenelzine are significantly related. The data suggest that the selective reversible MAO-A inhibitor brofaromine has a larger therapeutic safety than phenelzine. Clinical Pharmacology and Therapeutics (1989) 45, 260–269; doi:10.1038/clpt.1989.26
- Published
- 1989